HPGC Renmintongtai Pharmaceutical Corporation (600829) Fair Value & Analysis

Healthcare · CN · Market cap 6.1B CNY

A solid business, but screening 51% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥6.35). The favourable scenario is already priced in.
• Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.

How to read this chart

60‑month range ¥5.19 – ¥17.72 · fair‑value band ¥3.81 – ¥6.35 · the ¥10.32 price screens above the ¥5.08 fair value. Dashed = 300-day average. As of Aug 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

HPGC Renmintongtai Pharmaceutical Corporation (600829) currently trades at ¥10.32, while our model-based Fair Value estimate is ¥5.08, implying the stock looks roughly 50.8% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, HPGC Renmintongtai Pharmaceutical Corporation generated revenue of 10.5B CNY at a net margin of 1.3%. Revenue grew 5.9% year over year. It earns a return on equity of 4.6%. The balance sheet holds a net cash position of 230M CNY. Fundamentals as of Aug 9, 2026

Our scenario range runs from ¥3.81 (bear case) to ¥6.35 (bull case); at ¥10.32, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -51%, 600829 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth DCF (¥10.19) versus Dividend Discount (¥0.5200). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally.

Full company description

HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosmetics products. It also provides logistics services, including warehousing and distribution services; and hospital services comprising medical treatment, scientific research, prevention, health care, rehabilitation, and hemodialysis and kidney disease treatment. Further, it is involved in distribution of medical equipment and operation of Chinese medicine and outpatient clinics. It serves its products through e-commerce platform, a chain of direct stores and online B2C, O2O, etc. The company was founded in 1950 and is headquartered in Harbin, China. HPGC Renmintongtai Pharmaceutical Corporation is a subsidiary of Harbin Pharmaceutical Group Co., Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

HPGC Renmintongtai Pharmaceutical Corporation reported revenue of ¥10.4B in FY2025 versus ¥9.3B in FY2021, a compound +2.7%/yr. Reported net income was ¥134M in FY2025, compounding −16.6%/yr from FY2021.

600829 screens 51% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.